Why a Kidney Biopsy Is Often Recommended in Lupus Nephritis, and How Its Class Guides Care

Key Takeaways
- According to the NIH, as many as 5 out of 10 adults with lupus and about 8 out of 10 children develop lupus nephritis, often without any symptoms they can feel.
- Blood and urine tests can show that the kidney is leaking protein or blood, but only tissue can reveal which of the six ISN/RPS classes is present and how much is scar.
- Class III and class IV are separated by a single number: lesions in fewer than 50% of glomeruli versus 50% or more, which is why an adequate biopsy sample matters.
- The 2018 ISN/RPS revision added activity and chronicity indices, and these scores often influence treatment intensity as much as the class itself.
- Visible blood in the urine for up to about 24 hours after a kidney biopsy is expected, while strenuous activity is usually avoided for roughly two weeks.
- Repeat-biopsy studies show that quiet blood and urine tests do not guarantee quiet tissue, which is one reason maintenance treatment is not stopped without the prescriber's guidance.
A kidney biopsy is often recommended in lupus nephritis because blood and urine tests cannot show which pattern of kidney inflammation is present or how much scarring has already occurred. Pathologists grade the tissue into six ISN/RPS classes, from minimal involvement to advanced scarring, and that class, together with activity and chronicity scores, helps the treating team decide how intensive treatment should be.
The rheumatology appointment had gone well, right up until the last five minutes. Her lupus had been quiet for months. Then the nurse mentioned protein in the urine sample, and the doctor said a word she had only ever heard on television: biopsy. A needle in the kidney, for a problem she could not feel, seemed like a large step for a small number on a lab slip.
That reaction is common, and it is reasonable. So is the recommendation. Lupus nephritis kidney biopsy classes exist because the kidney does not report its own damage honestly. A urine test can say that something is leaking; it cannot say whether the filtering units are mildly irritated, actively inflamed, or already turning to scar.
This explainer walks through why the biopsy is suggested, what the procedure actually involves, what each class means, and how the result shapes the conversation about treatment. Nothing here replaces the advice of the team who know your kidneys; it is meant to make that conversation easier to follow.
What is systemic lupus erythematosus, and why does it reach the kidney?
Systemic lupus erythematosus (SLE) is an autoimmune disease: the immune system, which should attack infections, instead produces antibodies against the body’s own cells. Those antibodies bind to fragments of cell material and form immune complexes, small clumps of antibody stuck to its target. The bloodstream carries these clumps everywhere, and the kidney, which filters roughly all the blood in the body many times a day, is where they tend to settle.
Each kidney contains about a million glomeruli, microscopic tufts of capillaries that act as sieves. When immune complexes lodge in or around a glomerulus, they trigger inflammation. White blood cells arrive, the capillary walls thicken or leak, and protein and red blood cells that should stay in the blood slip into the urine. This process is lupus nephritis.
It is not rare. According to the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases, as many as 5 out of 10 adults with lupus develop lupus nephritis, and the figure is higher in children, around 8 out of 10. Many people are diagnosed with kidney involvement within the first years after lupus itself is recognized, which is why rheumatologists check urine so routinely.
Two features make lupus nephritis unusually hard to judge from the outside. First, it is often silent: the early stages produce no pain and no change a person would notice. Second, it is heterogeneous. One person’s glomeruli may show faint deposits with little inflammation; another’s may be crowded with inflammatory cells and crescents, the scar-forming arcs that signal severe injury. Those two people need very different conversations about treatment, yet their blood tests can look nearly identical. That gap between what tests show and what tissue shows is the whole case for a biopsy.
Why is a kidney biopsy for lupus recommended so often?
Think of the standard kidney tests as a smoke alarm. Protein in the urine, red blood cells seen under the microscope, a creatinine level that creeps upward: each one says there is a fire somewhere. None says what is burning or how far it has spread. The biopsy is the walk through the building.

Major rheumatology and nephrology guidelines, including those summarized by the NIH and the Mayo Clinic, describe the biopsy as the reference standard for confirming lupus nephritis and for classifying it. The reasons come down to three questions that only tissue can answer.
Which pattern is present? The six ISN/RPS classes, described later in this article, are defined by what the pathologist sees, not by what the patient feels. A membranous pattern and a diffuse proliferative pattern can both cause heavy protein loss, yet one tends to smolder while the other can damage filtering units within months.
How active is it? Inflammation that is current and reversible looks different under the microscope from damage that has already set into scar. Treatment aimed at calming the immune system can help the first; it cannot undo the second.
Is it even lupus? People with lupus can develop kidney problems unrelated to the disease, from medication effects to diabetes to clotting disorders linked to antiphospholipid antibodies. A biopsy occasionally reveals that the real culprit is something else entirely, which changes the plan completely.
Put simply, the biopsy converts a vague warning into a specific diagnosis with a specific intensity. The treatments used for serious lupus nephritis carry real side effects, so clinicians want to be sure they are matching the strength of the medicine to the strength of the disease. Starting intensive immunosuppression for a mild class, or gentle treatment for an aggressive one, are both mistakes that tissue can prevent.
What actually happens during a kidney biopsy?
Most lupus kidney biopsies are percutaneous, meaning through the skin, and are done with a thin needle guided by ultrasound. The description that follows draws on patient information from the NIH and the Mayo Clinic; your own team will explain any local differences.
Beforehand, you will usually have blood tests to check clotting and a blood count, and the team will ask about every medicine and supplement you take. Drugs that thin the blood, including some common pain relievers, are often paused for a period decided by the clinician. You may be asked not to eat for several hours.
On the day, you lie face down, often with a small pillow under the abdomen to push the kidney toward the back. The clinician uses ultrasound to locate the lower pole of one kidney, cleans and numbs the skin with a local anesthetic, and makes a tiny nick. A spring-loaded needle is advanced during a held breath, because the kidney moves with breathing, and it takes a core of tissue a little thicker than pencil lead. Most people feel pressure and hear a click; sharp pain is uncommon. Two or three cores are typical, so that the pathologist has enough glomeruli to classify confidently and to run the three types of analysis the ISN/RPS system requires: light microscopy, immunofluorescence (staining for antibody deposits) and electron microscopy (magnification high enough to see where deposits sit within the capillary wall).
The sampling itself takes minutes. The longer part is afterward. You will lie on your back for several hours while nurses check blood pressure, pulse and your first urine samples for bleeding. Some units observe people overnight; others send them home the same day if everything is stable. Either way, someone will need to drive you.
Children and adults who cannot lie still may be offered sedation. Rarely, when a percutaneous approach is unsafe, a surgical or transjugular biopsy through a neck vein is considered instead.
Who is usually offered a biopsy, and who is usually asked to wait?
Not every abnormal urine test leads straight to a needle. The decision balances how much the tissue result would change management against the small but real risks of the procedure.

A biopsy is most often recommended when there is persistent protein in the urine above the level the rheumatologist or nephrologist uses as a trigger, especially if red blood cells or cellular casts (tiny molds of the kidney tubules made of trapped cells) are also present. A rising creatinine, which signals falling filtration, raises the urgency considerably. New kidney findings in someone whose lupus has otherwise been stable are another classic prompt, as is a sudden change in someone already treated for nephritis, because the class can shift over time.
Guideline bodies summarized by the NIH and the Mayo Clinic generally favor biopsy before starting intensive immunosuppression, because the class determines which treatment pathway is appropriate.
Who tends to be asked to wait, or offered a different route?
- People with very mild, isolated abnormalities that may be monitored with repeat urine testing first, since transient protein leaks can follow fever, exercise or infection.
- People with uncontrolled high blood pressure, which must be brought down before a needle is placed, because pressure drives bleeding.
- People with abnormal clotting or very low platelet counts, who may need correction or a transjugular approach.
- People with a single functioning kidney, a kidney infection, or anatomical problems such as multiple cysts, where the risk calculation changes.
- Pregnancy, where timing and necessity are weighed case by case with obstetric input.
Occasionally the opposite happens: a patient asks to defer, and the team agrees to a short period of observation. That is a legitimate shared decision as long as everyone understands what is being traded. The risk of waiting is that active inflammation continues silently; the kidney does not send a reminder. The treating team, not a magazine, should weigh that trade for your situation.
Lupus nephritis classes explained: the six ISN/RPS categories
The International Society of Nephrology and Renal Pathology Society (ISN/RPS) classification sorts lupus nephritis into six classes by where immune deposits sit and how many glomeruli are involved. It was revised in 2018 (Bajema and colleagues, PubMed) to sharpen definitions and to add standardized activity and chronicity scoring. The classes are not a ladder that every patient climbs; a person can be diagnosed at any class, and some classes coexist.
| Class | Name | What the pathologist sees | Typical clinical picture |
|---|---|---|---|
| I | Minimal mesangial | Deposits in the mesangium (the glomerular support tissue) with no visible structural change on light microscopy | Usually silent; often normal urine |
| II | Mesangial proliferative | Mesangial deposits with increased mesangial cells | Mild protein or blood in urine |
| III | Focal | Active or scarred lesions in fewer than 50% of glomeruli | Variable; may include hematuria, protein loss, raised creatinine |
| IV | Diffuse | Lesions in 50% or more of glomeruli | Often the most active; higher risk of falling kidney function |
| V | Membranous | Deposits along the outer capillary wall, thickening it | Heavy protein loss, swelling; can coexist with III or IV |
| VI | Advanced sclerosing | 90% or more of glomeruli globally scarred | Chronic kidney failure; inflammation largely burned out |
A few points deserve emphasis. The split between class III and class IV is purely numerical, under or at 50% of glomeruli involved, which is why pathologists need an adequate number of glomeruli in the sample to call it reliably. Class V can be diagnosed on its own or stacked on top of III or IV, written as a combined class, and that combination matters because membranous disease responds to a somewhat different approach. Class VI describes the end of the road for inflammation-directed treatment; the damage is structural, and care shifts toward protecting what function remains.
Class, in other words, is a map of the terrain. The next layer tells you what the weather is doing.
How lupus nephritis kidney biopsy classes guide treatment decisions
The class is the headline, but modern pathology reports carry two further numbers that clinicians read just as closely: the activity index and the chronicity index. Both were made standard in the 2018 ISN/RPS revision.
The activity index scores features of live inflammation: too many cells inside glomeruli, white blood cells invading, deposits that look like wire loops in the capillary walls, cellular crescents, and inflammation in the surrounding tubules. High activity means the fire is burning now, and it is the part of the picture most likely to respond to immune-calming treatment.
The chronicity index scores what has already become permanent: glomeruli that are globally scarred, fibrous crescents, shrunken tubules and scar tissue between them. High chronicity means the damage is set. No medicine reverses scar; treatment here is about slowing further loss.
Here is how clinicians typically read the combinations, as reflected in NIH and Mayo Clinic summaries of guideline practice.
Classes I and II with little activity are usually managed by treating the lupus itself and watching the kidney. Aggressive immunosuppression is generally not justified, because the risk of the medicines would outweigh the risk from the kidney.
Classes III and IV, particularly with a high activity index, are the situations where guidelines recommend combination immunosuppression, often described as an induction phase to bring inflammation under control followed by a longer maintenance phase to keep it quiet. The presence of crescents or a rapid rise in creatinine pushes the urgency higher.
Class V alone, with heavy protein loss, is often treated with a blend of immunosuppression and measures to reduce protein leakage and protect blood vessels. When V coexists with III or IV, the proliferative class drives the plan.
Class VI, or any class with overwhelming chronicity, calls for a different conversation: blood pressure control, kidney-protective measures and, where filtration is severely reduced, planning for dialysis or transplant.
None of these pathways is automatic. The same class in a 19-year-old with normal creatinine and in a 55-year-old with diabetes may be approached differently, and that judgment belongs to the treating team.
What are the common medications used to treat nephritis?
People often ask what they might be offered once the class is known. The honest answer is a menu of classes of medicine rather than a single prescription, and the choice depends on the biopsy, kidney function, prior treatment, age, pregnancy plans and personal risk. What follows describes mechanism and typical roles only; no part of it is a recommendation, and every decision sits with the prescribing clinician.
Glucocorticoids (steroids) act broadly and quickly to dampen inflammation. Guidelines increasingly favor using them at the lowest effective intensity for the shortest necessary period, because long courses carry well-known effects on bone, blood sugar, weight and infection risk.
Antimalarials, in practice hydroxychloroquine, are recommended for nearly everyone with lupus unless there is a specific reason not to. They modulate immune signaling and are associated in observational research with fewer flares and less organ damage. Regular eye checks are part of using them.
Antimetabolites such as mycophenolate slow the multiplication of the lymphocytes that drive the autoimmune attack, and are a mainstay for both induction and maintenance in proliferative classes. Cyclophosphamide, an older cytotoxic agent, is sometimes used for severe or rapidly progressive disease; its fertility and bladder effects are the reason it is reserved rather than routine.
Calcineurin inhibitors, including tacrolimus and the newer voclosporin, block activation of T cells and also stabilize the filtering cells of the glomerulus, which is why they reduce protein loss relatively quickly. Biologic agents such as belimumab target B-cell survival signals; some guideline bodies now include them as add-on therapy in active nephritis.
Alongside the immune drugs sit kidney-protective measures: ACE inhibitors or ARBs to lower pressure inside the glomerulus and reduce protein leak, blood pressure control, lipid management and, in some cases, anticoagulation when antiphospholipid antibodies are present.
Timelines are measured in months. Induction is generally judged over the first several months, and maintenance continues for years, because stopping too early is a recognized cause of relapse, according to NIH and Mayo Clinic summaries. If you are considering changing anything, the conversation starts with the person who prescribed it.
What do the days and weeks after a kidney biopsy usually look like?
The first hours are the most carefully watched. After the needle comes out, pressure is held on the site, a dressing is applied, and you lie flat so that the small puncture in a very vascular organ can seal. Nurses check vital signs on a schedule and look at each urine sample. A pink or faintly red tinge in the first one or two is expected; the NIH and the Mayo Clinic both describe visible blood in the urine for up to about 24 hours as a common and usually harmless finding.
The back feels bruised for a few days. Mild aching that eases with rest and simple analgesia agreed with your team is typical. Many people return to desk work within a day or two, but both sources advise avoiding heavy lifting, contact sport and strenuous exercise for roughly two weeks, because a sudden strain can reopen bleeding at the biopsy site. Blood thinners are restarted only when the clinician says so.
Then comes the waiting, which people often find harder than the procedure. Light microscopy results can be available within days; immunofluorescence and electron microscopy, plus the activity and chronicity scoring, usually take longer, so a complete report commonly arrives in one to two weeks. Some teams start treatment on preliminary findings when the clinical picture is urgent, then refine the plan.
Expect a follow-up appointment where the class and indices are explained and a treatment pathway is proposed. It helps to bring someone with you and to ask for the report in writing. Terms such as crescents, wire loops and tubular atrophy will appear; each is simply a description of what was seen, and your team can translate them.
In the weeks that follow, monitoring is steady rather than dramatic: urine protein, urine sediment, creatinine, blood pressure and complement levels, repeated at intervals the team sets. Improvement in these numbers over months, not days, is how response is judged.
What are the risks, and are there alternatives to a kidney biopsy for lupus?
A biopsy is a minor procedure on a major organ, and the risks deserve plain language.
Bleeding is the main one. The kidney receives a large share of the body’s blood flow, so any puncture can bleed. Most bleeding is trivial and stops on its own; it shows up as the brief hematuria described above or as a small bruise around the kidney seen only on scans. A smaller number of people have bleeding significant enough to need extended observation, a blood transfusion or, uncommonly, a procedure to block the bleeding vessel. The Mayo Clinic lists these as recognized but uncommon complications; the precise frequency varies with the person’s blood pressure, clotting and kidney function, which is why those are checked first.
Pain at the site is usual and short-lived. Infection is rare because the puncture is tiny and the skin is sterilized. An arteriovenous fistula, an abnormal connection between an artery and vein inside the kidney, can form and usually closes by itself. Injury to nearby organs is very rare with ultrasound guidance.
An inadequate sample, with too few glomeruli to classify, happens occasionally and may mean a repeat procedure. This is one reason pathologists prefer more than one core.
As for alternatives, the candid answer is that none currently matches tissue. Blood markers such as anti-double-stranded DNA antibodies and complement levels track lupus activity in general but correlate only loosely with what is happening in the kidney. Urine protein quantifies leakage without revealing the pattern. Imaging shows size and structure, not inflammation. Research into urine and blood biomarkers that could predict class is active and promising, but as the NIH notes, none has replaced biopsy in guideline practice.
The real alternative, then, is informed observation: repeat urine and blood testing over weeks, with a biopsy if abnormalities persist or worsen. For mild findings that is a reasonable path. For more worrying ones, clinicians usually explain that waiting carries its own risk.
Lupus nephritis symptoms: ankle swelling, blood in the urine, and the signs that hide
Can lupus cause ankle swelling? Yes, and when it does in someone with lupus, the kidney is one of the first places doctors look. Healthy glomeruli hold on to albumin, the main protein in blood that keeps fluid inside vessels. When inflamed or thickened capillary walls let albumin escape into the urine, blood protein falls, fluid seeps into tissues, and gravity pulls it to the ankles and feet by evening. Puffiness around the eyes on waking, and sometimes abdominal swelling, come from the same leak. Urine may look foamy because of the protein.
Can lupus nephritis cause blood in the urine? It can, though usually not visibly. Red blood cells slipping through damaged glomeruli are most often found only under the microscope, sometimes shaped into casts that identify the glomerulus as the source. Visible red or cola-colored urine is less common and should always be reported promptly.
Other features described by MedlinePlus, the NHS and the Mayo Clinic include high blood pressure that is new or harder to control, weight gain from fluid, reduced urine output, and in advanced disease the nonspecific tiredness, nausea and loss of appetite that come with falling kidney function.
The signs that hide are the ones that matter most. Classes I, II and early III may produce nothing a person can feel, which is why routine urine testing at every rheumatology visit is standard practice rather than caution for its own sake. A dipstick and a protein-to-creatinine ratio on a single sample cost minutes and catch problems years before symptoms.
Two cautions. Swollen ankles have many causes, from heat and prolonged sitting to heart or liver problems and some medicines, and none of these features is specific enough to diagnose nephritis on its own. This section is not a checklist for self-diagnosis; it is a guide to what deserves a phone call and a urine test.
When is a repeat kidney biopsy in lupus considered?
One biopsy describes one moment. Lupus nephritis is not static: a person who began with a membranous pattern may develop proliferative lesions later, inflammation may settle into scar, and the balance between activity and chronicity shifts with treatment. That is why repeat biopsies come up, and why the subject is debated among specialists.
In current practice, a repeat biopsy is most often considered in three situations. The first is a clear change in the clinical picture during or after treatment, for example a new rise in creatinine or a jump in protein loss, where the team needs to know whether this is a flare of active disease, progression to a different class, treatment-related injury or something unrelated. The second is persistent abnormal urine findings despite months of treatment, where the question is whether to intensify therapy or accept that the remaining abnormality reflects fixed scar. The third is uncertainty about whether maintenance treatment can safely be reduced.
That third use is the contentious one. Observational studies, including protocol repeat-biopsy series indexed on PubMed, have reported that a meaningful share of patients whose urine and blood tests look quiet still show active inflammation on tissue, and conversely that some with lingering protein loss have mainly chronic damage. Those findings suggest that clinical remission and histological remission are not the same thing. What the evidence does not yet settle is whether routinely repeating the biopsy to guide stopping treatment improves long-term outcomes compared with careful clinical monitoring. Some centers use protocol repeat biopsies; many do not; guidelines generally describe them as reasonable in selected cases rather than mandatory.
The same risk and preparation considerations apply as for the first procedure, and the person’s current blood pressure, platelet count and anticoagulation are rechecked. Whether a second look is worth it for you is a conversation about what would change as a result, and it belongs with your nephrologist and rheumatologist together.
What people often get wrong about lupus nephritis and biopsy
Myths gather around any procedure involving a needle and an organ. These are the ones clinicians hear most, with what the evidence actually shows.
“If my kidney tests are only a little abnormal, the biopsy will be mild too.” Not reliably. The correlation between urine findings and class is loose. Studies summarized by the NIH note that people with modest protein loss can have class IV disease on tissue, and the whole point of the biopsy is that it cannot be predicted from the outside.
“The biopsy removes part of my kidney.” The cores taken are tiny slivers, a few millimeters across, from an organ containing around a million glomeruli. Function is not reduced by the sampling.
“A high class means I will need dialysis.” Class describes pattern, not destiny. A class IV result with high activity and low chronicity is exactly the situation where treatment has the most to offer, because the damage is inflammatory and potentially reversible. Outcomes depend on how quickly inflammation is controlled and on long-term adherence, not on the Roman numeral alone.
“The classes go in order, so I will progress from II to VI.” The numbering is a catalog, not a staircase. Many people never move class; some move in either direction.
“Once the urine is clear, I can stop the medicines.” Clinical quietness and tissue quietness are different, as the repeat-biopsy literature shows, and stopping maintenance early is a recognized trigger for relapse. Any change is a decision made with the prescriber, never alone.
“Lupus nephritis is always painful.” It is more often painless. Flank pain in someone with lupus points more toward stones, infection or muscle strain and deserves its own assessment.
“The biopsy will show whether my lupus is severe overall.” It shows the kidney. Lupus can be active in the skin, joints or blood while the kidney is quiet, and vice versa.
Questions to ask your care team before and after the biopsy
Good questions do not challenge your team; they help them explain. Bring a list, bring a companion, and ask for answers you can take home in writing.
Before the procedure, consider asking:
- What specifically are you hoping the biopsy will tell us that current tests cannot, and how would each likely result change the plan?
- Which of my medicines or supplements should pause beforehand, for how long, and who will tell me when to restart them?
- What is my personal bleeding risk given my blood pressure, platelet count and kidney function, and what will be done to reduce it?
- Will I stay overnight, and who do I call if something changes once I am home?
- If the sample turns out to be inadequate, what happens next?
When the results arrive:
- What class was found, and does the report include activity and chronicity indices? What do my numbers mean in plain terms?
- How much of what you saw looks reversible, and how much is scar?
- Was anything found that is not lupus, such as vascular changes or signs of antiphospholipid-related clotting?
- Which treatment pathway are you proposing, what is it meant to achieve, and over what timescale will we judge whether it is working?
- What side effects should I watch for, and what monitoring will I need, including eye checks, blood counts and infection precautions?
- How will this plan affect pregnancy, fertility or vaccinations, if those matter to me?
- Under what circumstances would you consider a repeat biopsy?
It is also fair to ask whether the pathologist reporting the sample specializes in kidney disease, and whether your rheumatologist and nephrologist are communicating directly. Lupus nephritis sits between two specialties, and the best plans are built where they overlap. If an answer is not clear, say so and ask again; a team that explains well is a team you can follow over the years this condition usually requires.
When to call your doctor
Two sets of warning signs matter here: those related to the biopsy itself, and those that may signal the nephritis is changing.
After a biopsy, contact the team or seek urgent care if you notice any of the following, which the NIH and Mayo Clinic list as reasons for prompt review:
- Urine that stays visibly bloody beyond the first day, becomes darker, or contains clots.
- Inability to pass urine.
- Worsening pain in the back, flank or abdomen, or pain that does not ease with rest.
- Dizziness, faintness, a racing heart, or feeling cold and clammy, which can indicate internal bleeding.
- Fever, chills, or redness and discharge at the puncture site.
Sudden severe pain with faintness is an emergency; call emergency services rather than waiting for a callback.
At any time during life with lupus nephritis, the following deserve a same-day call to your rheumatology or nephrology team:
- New or rapidly increasing swelling of the ankles, legs, face or abdomen, or sudden weight gain over a few days.
- Urine that looks red, brown or cola-colored, or that becomes persistently foamy.
- A marked fall in how much urine you pass.
- Blood pressure readings much higher than your usual, especially with headache, blurred vision or chest discomfort.
- Shortness of breath when lying flat, which can reflect fluid overload.
- Fever or signs of infection while on immunosuppressive treatment, since these medicines blunt the body’s response and infections can escalate quickly.
- Persistent nausea, vomiting, confusion or extreme fatigue, which can accompany worsening kidney function.
None of these signs diagnoses anything on its own, and many have innocent explanations. The point of calling is to let someone who knows your history decide whether a urine test, a blood test or a visit is needed today. With lupus nephritis, earlier is nearly always easier than later, and your treating team would rather hear from you than not.
Frequently asked questions
What is systemic lupus erythematosus?
Systemic lupus erythematosus is a chronic autoimmune disease in which the immune system makes antibodies against the body’s own cells, forming immune complexes that inflame skin, joints, blood, and organs including the kidney. It varies widely between people and over time, with flares and quieter periods. Kidney involvement, called lupus nephritis, is among its most serious complications and is screened for with routine urine tests.
Why is a kidney biopsy for lupus recommended when my blood tests already show lupus?
Because blood tests confirm lupus but cannot show what is happening inside the kidney. A biopsy identifies the ISN/RPS class, scores active inflammation against permanent scar, and rules out non-lupus causes of kidney damage. Those findings determine whether gentle monitoring or intensive immunosuppression is appropriate, which is why guidelines generally recommend tissue before starting stronger treatment.
Can lupus nephritis cause blood in the urine?
Yes. Inflamed glomeruli can let red blood cells pass into the urine, usually in amounts seen only under a microscope, sometimes formed into casts that point to the glomerulus as the source. Visibly red or brown urine is less common and should be reported the same day, both because it may signal active nephritis and because other causes, such as infection or stones, need to be excluded.
Can lupus cause ankle swelling?
It can, most often through the kidney. When damaged glomeruli leak albumin into the urine, blood protein levels fall and fluid shifts into the tissues, pooling in the ankles by the end of the day and around the eyes on waking. Swelling has many other causes, so new or worsening puffiness in someone with lupus is a reason for a urine protein test rather than a diagnosis in itself.
Are the lupus nephritis classes explained as stages that get worse in order?
No. The six ISN/RPS classes are categories based on where immune deposits sit and how many glomeruli are affected, not sequential stages. A person may be diagnosed at any class, stay there, or shift in either direction over time. Class VI describes advanced scarring, but a high-numbered proliferative class with active inflammation and little scar is often the situation where treatment has the most to offer.
What is the difference between lupus nephritis class 4 and class 3?
Both describe proliferative inflammation in the glomeruli; the difference is extent. Class III, called focal, involves fewer than 50% of glomeruli, while class IV, called diffuse, involves 50% or more. Class IV is more often associated with falling kidney function and higher activity scores, and both are usually treated along similar immunosuppressive pathways, with intensity guided by the activity and chronicity indices.
What are the common medications used to treat nephritis?
Guideline-based care typically combines an antimalarial such as hydroxychloroquine, glucocorticoids used as sparingly as possible, and an immunosuppressant such as mycophenolate, with calcineurin inhibitors, cyclophosphamide or biologic agents considered in specific situations. Kidney-protective drugs such as ACE inhibitors or ARBs and blood pressure control run alongside. Which combination suits a given person depends on class, kidney function and individual risk, and is decided by the prescribing team.
How long does a kidney biopsy take, and how long until results?
The needle sampling itself takes only minutes, but preparation and the several hours of lying flat afterward make it a half-day or overnight commitment. Preliminary light microscopy findings may be available within days, while the full report with immunofluorescence, electron microscopy and activity and chronicity scoring commonly takes one to two weeks, according to patient information from the NIH and the Mayo Clinic.
When is a repeat kidney biopsy in lupus nephritis considered?
Most often when the clinical picture changes during or after treatment, when abnormal urine findings persist despite months of therapy, or when the team is deciding whether maintenance treatment can safely be reduced. Observational studies show that quiet blood and urine tests do not always mean quiet tissue, but whether routine repeat biopsies improve outcomes is still debated, so they are used selectively rather than universally.
What are the main risks of a kidney biopsy?
Bleeding is the principal risk, usually limited to a day of pink-tinged urine or a small bruise around the kidney, with a minority needing longer observation or a transfusion. Pain at the site, rare infection, an arteriovenous fistula that typically closes on its own, and an inadequate sample requiring repeat are the other recognized issues. Checking blood pressure and clotting beforehand is how teams keep these risks low.
References
- Lupus Nephritis – National Institute of Diabetes and Digestive and Kidney Diseases (NIH)
- Kidney Biopsy – National Institute of Diabetes and Digestive and Kidney Diseases (NIH)
- Lupus nephritis – MedlinePlus Medical Encyclopedia
This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.
More from the Blog
How Long Until Juvenile Idiopathic Arthritis Treatment Starts to Help? A Realistic Timeline
Most children with juvenile idiopathic arthritis start to feel some relief within days to a few weeks once anti-inflammatory treatment begins, but the disease-modifying…
Staying on SLE Medication Between Flares: What the Monitoring Tests Are Looking For
People with systemic lupus erythematosus (SLE) are usually asked to keep taking maintenance medicines between flares because these drugs quiet immune activity before damage…
Eye Pain, Fever or Severe Swelling With Reactive Arthritis: When Follow-Up Cannot Wait
With reactive arthritis, new eye pain, light sensitivity or blurred vision, a fever, or one joint that becomes hot, very swollen and impossible to…
Vaccination Planning During Long-Term Vasculitis Therapy: What Your Team Schedules and Why
People receiving long-term immunosuppression for vasculitis can and should receive most vaccines, but timing matters. Non-live vaccines such as influenza, pneumococcal, COVID-19 and recombinant…
Why Lung Function Tests and Echocardiography Come Early in Scleroderma Treatment
Lung function tests and echocardiography are ordered early in scleroderma because the two complications most likely to shorten life, interstitial lung disease and pulmonary…
X-Ray or MRI for Ankylosing Spondylitis: What Each Scan Shows Your Rheumatologist
Rheumatologists use both scans for different jobs. An X-ray shows structural bone damage in the sacroiliac joints or spine, such as erosions, sclerosis and…






